Smital Shah

CIK 1808821 · Chief Fin. and Bus. Officer · last filed 2026-03-16

Smital Shah is a Chief Fin. and Bus. Officer who has filed 8 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for LYEL, was dated Mar 16, 2026. Across all open-market trades the lifetime net is +$100.0K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

Companies

Total Filings

Lifetime Open-Market Net

$100.0K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address

C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO, CA

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
LYEL	Chief Fin. and Bus. Officer	—	$9.26	—	$0	1	2026-03-16
PLRX	Director	—	$1.03	—	$0	4	2024-06-17
LENZ Therapeutics, Inc. (GRPH) Delisted	Director	840	$22.26	$18.7K	$100.0K	3	2023-07-21

Recent Filings

8 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-03-16	LYEL	Grant (A)	—	$0	EDGAR
2024-06-17	PLRX	Grant (A)	—	$0	EDGAR
2023-07-21	LENZ Therapeutics, Inc. (GRPH) Delisted	Grant (A)	—	$0	EDGAR
2023-06-08	PLRX	Grant (A)	—	$0	EDGAR
2022-06-22	LENZ Therapeutics, Inc. (GRPH) Delisted	Grant (A)	—	$0	EDGAR
2022-06-21	PLRX	Grant (A)	—	$0	EDGAR
2021-07-01	LENZ Therapeutics, Inc. (GRPH) Delisted	Mixed	+5,882	$100.0K	EDGAR
2021-06-30	PLRX	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.